Literature DB >> 832447

Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response.

D Raft, J Gregg, J Ghia, L Harris.   

Abstract

Two intravenous doses of tetrahydrocannabinol (THC) (0.022 mg/kg and 0.044 mg/kg) were compared to intravenous diazepam (0.157 mg/kg) and to placebo (Ringer's lactate) as premedication for dental extraction in 10 healthy volunteers. Pain detection and tolerance thresholds were measured and psychiatric interviews were supplemented by Minnesota Multiphasic Personality Inventories (MMPI), the Zung Depression Scale (ZDS), Beck Depression Inventories (BDI), and the State-Trait Anxiety Inventory (STAI). Pain detection thresholds were altered unpredictably with high THC doses, but analgesia as indicated by pain tolerance was less than that after diazepam and placebo. In three subjects low-dose THC (0.022 mg/kg) was a better analgesic than placebo but not diazepam. Six subjects preferred placebo to low-dose THC as an analgesic; this group experienced increases in subjective surgical pain and were submissive, rigid, and less introspective with high State Anxiety and MMPI profiles that differed from subjects whose pain was not increased. STAI following THC presaged a poor analgesic response in this group.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832447     DOI: 10.1002/cpt197721126

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

Review 1.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

Authors:  F A Campbell; M R Tramèr; D Carroll; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

2.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

3.  Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats.

Authors:  Krista J Spiller; Guo-Hua Bi; Yi He; Ewa Galaj; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2019-04-03       Impact factor: 8.739

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 6.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

7.  The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.

Authors:  M L Uhelski; D M Cain; C Harding-Rose; D A Simone
Journal:  Neuroscience       Date:  2013-05-11       Impact factor: 3.590

Review 8.  Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.

Authors:  Bjorn Jensen; Jeffrey Chen; Tim Furnish; Mark Wallace
Journal:  Curr Pain Headache Rep       Date:  2015-10

Review 9.  The therapeutic potential of cannabis and cannabinoids.

Authors:  Franjo Grotenhermen; Kirsten Müller-Vahl
Journal:  Dtsch Arztebl Int       Date:  2012-07-23       Impact factor: 5.594

10.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

Authors:  J Manzanares; Md Julian; A Carrascosa
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.